Pepdox
Studies
Peptides
Calculator
Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5analysis. | Pepdox
Home
/
Search
/
PMID 42131512
Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5analysis.
European heart journal open
2026
PMID: 42131512
View on PubMed
DOI: 10.1093/ehjopen/oeag071
Semaglutide
Tirzepatide
Authors
Ghosal, Samit; Sinha, Binayak